GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TransMedics Group Inc (STU:TMDX) » Definitions » EV-to-Revenue

TransMedics Group (STU:TMDX) EV-to-Revenue : 14.48 (As of May. 03, 2024)


View and export this data going back to 2023. Start your Free Trial

What is TransMedics Group EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, TransMedics Group's enterprise value is €3,971.4 Mil. TransMedics Group's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €274.2 Mil. Therefore, TransMedics Group's EV-to-Revenue for today is 14.48.

The historical rank and industry rank for TransMedics Group's EV-to-Revenue or its related term are showing as below:

STU:TMDX' s EV-to-Revenue Range Over the Past 10 Years
Min: 6.92   Med: 16.44   Max: 43.36
Current: 17.97

During the past 8 years, the highest EV-to-Revenue of TransMedics Group was 43.36. The lowest was 6.92. And the median was 16.44.

STU:TMDX's EV-to-Revenue is ranked worse than
86.29% of 824 companies
in the Medical Devices & Instruments industry
Industry Median: 3.235 vs STU:TMDX: 17.97

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-03), TransMedics Group's stock price is €111.40. TransMedics Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €8.25. Therefore, TransMedics Group's PS Ratio for today is 13.51.


TransMedics Group EV-to-Revenue Historical Data

The historical data trend for TransMedics Group's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TransMedics Group EV-to-Revenue Chart

TransMedics Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial 15.09 17.54 15.99 19.80 11.17

TransMedics Group Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.61 17.67 9.78 11.17 -

Competitive Comparison of TransMedics Group's EV-to-Revenue

For the Medical Devices subindustry, TransMedics Group's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TransMedics Group's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, TransMedics Group's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where TransMedics Group's EV-to-Revenue falls into.



TransMedics Group EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

TransMedics Group's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=3971.413/274.209
=14.48

TransMedics Group's current Enterprise Value is €3,971.4 Mil.
TransMedics Group's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €274.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TransMedics Group  (STU:TMDX) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

TransMedics Group's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=111.40/8.246
=13.51

TransMedics Group's share price for today is €111.40.
TransMedics Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €8.25.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TransMedics Group EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of TransMedics Group's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


TransMedics Group (STU:TMDX) Business Description

Traded in Other Exchanges
Address
200 Minuteman Road, Andover, MA, USA, 01810
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body.